Development of Advanced Preclinical Models for Pediatric Solid Tumors

儿科实体瘤先进临床前模型的开发

基本信息

项目摘要

PROJECT SUMMARY Pediatric solid tumors are a rare and highly heterogeneous collection of cancers. For many subtypes, progress in defining novel therapies has stalled over the last 10-20 years. Indeed, for most of these tumors chemotherapy continues to be the primary form of treatment and targeted therapies are not available. This lack of progress is likely due at least in part to the difficulty in developing clinical trials for individual histologic subtypes given their rarity. An alternative is to develop a robust preclinical testing program. Currently, such programs are limited by the lack of well-credentialed models that incorporate the most advanced technologies for genomic and functional characterization and do to the lack of good models for therapy-resistant and metastatic disease. Here we bring together two PIs with complimentary expertise to develop new approaches for validation and preclinical use of pediatric solid tumor animal models. Our focus is on the use of patient- derived xenografts for three most common histotypes: osteosarcoma, ewing sarcoma and rhabdomyosarcoma. PDX models are particularly well suited for studying highly heterogeneous tumors such as pediatric solid tumors. In Aim 1, we will develop novel advance PDX models that incorporate two key innovations: i) utilization of CRISPR/CAS9 technology for genetic interrogation and ii) autologous and allogeneic approaches for development of PDX models with a human immune system (hu-PDX). In Aim 2, we will develop novel computational tools to assess the similarity of PDX models to their tumor of origin and to evaluate human- mouse and mouse-mouse evolution which may impact clinical relevance. We will work closely with members of the Oncology Models Forum to develop scoring systems to assess this similarity and make these tools widely available to the modeling community. In Aim 3, we will evaluate intratumor heterogeneity during human-mouse and mouse-mouse evolution of PDX models using single cell RNAseq. We expect that the tools and models developed here will be widely applicable to other PDX models and that the specific models we develop will help facilitate preclinical research. We will make all tools and models widely accessible to the research community.
项目摘要 儿童实体瘤是一种罕见的高度异质性癌症。对于许多亚型, 在过去的10-20年里,在定义新疗法方面已经停滞不前。事实上,对于大多数肿瘤来说, 化疗仍然是治疗的主要形式,并且没有靶向治疗。这 缺乏进展可能至少部分是由于难以开展针对个体组织学的临床试验, 因为它们很罕见另一种方法是开发一个强大的临床前测试程序。目前,此类 由于缺乏具有最先进技术的可靠模型, 基因组和功能表征,并做缺乏良好的模型,治疗耐药, 转移性疾病在这里,我们汇集了两个具有互补专业知识的PI,以开发新的方法 用于儿科实体瘤动物模型的验证和临床前使用。我们的重点是病人的使用- 三种最常见的组织型:骨肉瘤、尤文肉瘤和横纹肌肉瘤。 PDX模型特别适用于研究高度异质性肿瘤,如儿科实体瘤, 肿瘤的在目标1中,我们将开发新的先进PDX模型,其中包含两个关键创新:i)利用率 CRISPR/CAS9技术用于基因询问,以及ii)自体和同种异体方法用于 开发具有人免疫系统的PDX模型(hu-PDX)。在目标2中,我们将开发新的 计算工具,以评估PDX模型与其肿瘤来源的相似性,并评估人类- 小鼠和小鼠-小鼠进化可能影响临床相关性。我们将与各成员国密切合作, 肿瘤模型论坛开发评分系统,以评估这种相似性,并使这些工具广泛 提供给模特界。在目标3中,我们将评估人-小鼠实验期间的肿瘤内异质性。 以及使用单细胞RNAseq的PDX模型的小鼠-小鼠进化。我们希望这些工具和模型 这里开发的将广泛适用于其他PDX模型,我们开发的特定模型将 有助于促进临床前研究。我们将使所有工具和模型广泛用于研究 社区

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID H HAUSSLER其他文献

DAVID H HAUSSLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID H HAUSSLER', 18)}}的其他基金

Data Resource and Administrative Coordination Center for the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes Consortium
精神科和神经发育障碍风险基因联盟的可扩展和系统神经生物学数据资源和行政协调中心
  • 批准号:
    10642251
  • 财政年份:
    2023
  • 资助金额:
    $ 58.95万
  • 项目类别:
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources
增强 UCSC Xena:将交互式可视化扩展到超大规模多组学数据并与分析资源集成
  • 批准号:
    10687189
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Center for Live Cell Genomics
活细胞基因组学中心
  • 批准号:
    10307037
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources
增强 UCSC Xena:将交互式可视化扩展到超大规模多组学数据并与分析资源集成
  • 批准号:
    10187394
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources
增强 UCSC Xena:将交互式可视化扩展到超大规模多组学数据并与分析资源集成
  • 批准号:
    10430132
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Center for Live Cell Genomics
活细胞基因组学中心
  • 批准号:
    10676332
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Nanoparticle Tracking Analyzer (NTA) for the Center for Live Cell Genomics
用于活细胞基因组学中心的纳米颗粒跟踪分析仪 (NTA)
  • 批准号:
    10817569
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
Enabling Comparative Pangenomics
实现比较泛基因组学
  • 批准号:
    10555318
  • 财政年份:
    2020
  • 资助金额:
    $ 58.95万
  • 项目类别:
Development of Advanced Preclinical Models for Pediatric Solid Tumors
儿科实体瘤先进临床前模型的开发
  • 批准号:
    10579262
  • 财政年份:
    2020
  • 资助金额:
    $ 58.95万
  • 项目类别:
Center for Big Data in Translational Genomics
转化基因组学大数据中心
  • 批准号:
    9277519
  • 财政年份:
    2014
  • 资助金额:
    $ 58.95万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 58.95万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 58.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了